Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged In Phase II/III Marvel Trial Of Myogenic Cells For Treating Advanced Heart Failure

Bioheart, Inc., (Nasdaq: BHRT), announced that 35 of the leading U.S. Heart Failure Centers have engaged in Bioheart's Phase II/III MARVEL(1) Trial of myogenic cells for treating advanced heart failure. "With 35 leading heart failure centers engaged, we are making tremendous progress in patient screening and enrollment," said Dr.